Once-daily AUSTEDO XR® (deutetrabenazine) extended release tablets reduce uncontrollable Tardive Dyskinesia (TD) body movements. See safety info including Boxed Warning.

AUSTEDO XR ® (deutetrabenazine) extended-release tablets and AUSTEDO ® (deutetrabenazine) tablets are indicated in adults for the treatment of chorea associated with Huntington’s disease and …

Aug 20, 2025 · Austedo's drug class is a VMAT2 inhibitor (vesicular monoamine transporter 2 inhibitor). Austedo tablets are taken twice daily, and the Austedo XR (extended-release) tablets are taken once …

Oct 22, 2025 · She added, “These data articulate patient experience and further validate clinical research showing how AUSTEDO or AUSTEDO XR can help people living with tardive dyskinesia …

Nov 7, 2025 · The most common adverse reactions for AUSTEDO (4% and greater than placebo) in controlled clinical studies in patients with tardive dyskinesia were nasopharyngitis and insomnia. …

Learn about once-daily dosages for AUSTEDO XR® (deutetrabenazine) extended release tablets for Tardive Dyskinesia (TD). See safety info and Boxed Warning.

May 29, 2024 · U.S. FDA approves new one pill, once-daily AUSTEDO XR tablets (30, 36, 42, 48 mg/day) AUSTEDO XR offers more flexibility with the most once-daily doses of any vesicular …

Resources for each step of the treatment journey with AUSTEDO XR Teva is committed to supporting your patients with tardive dyskinesia (TD) and their care partners.

Sep 25, 2025 · Austedo and Austedo XR treat tardive dyskinesia and chorea related to Huntington’s disease in adults. The dosage varies depending on the condition. Austedo typically starts at 6 mg …

Jun 1, 2024 · In a significant advancement for those suffering from tardive dyskinesia (TD), the U.S. Food and Drug Administration (FDA) recently approved Austedo XR (extended-release …